Microsoft word - 090902 press release-astelin jv purchase.doc
News Release MEDPOINTE ACQUIRES 100% OF ASTELIN® RIGHTS IN US AND CANADA
Acquires Joint Venture Interest, Intellectual Property Not Already Owned
SOMERSET, NJ – September 9, 2002 – In its third strategic move this year designed to
capture the full commercial potential of its flagship product, the anti-allergy nasal spray
ASTELIN®, MedPointe announced today it has acquired exclusive, royalty-free US and
Canadian rights to this FDA-approved prescription pharmaceutical, including associated
Prior to the transaction, the product’s US commercial rights were owned by a Joint
Venture between MedPointe (60% owner) and Asta Medica, Inc. (40%), a wholly-owned
subsidiary of Viatris GmbH & Co. KG. Viatris will continue to provide to MedPointe the
product’s active ingredient, azelastine, under a negotiated long-term supply agreement.
The purchase price and the terms of the long-term supply agreement were not disclosed.
The transaction follows closely on the heels of MedPointe’s earlier announcement that its
prescription pharmaceutical division, Wallace Pharmaceuticals, has entered into a multi-
year ASTELIN co-promotion arrangement with Sepracor (NASDAQ: SEPR), whereby
Sepracor’s 450-person sales force will co-promote the product in the US to an array of
physician specialists, including pediatricians, allergists, ENTs, pulmonologists, and
primary care physicians. Also, earlier this year, in an effort to raise ASTELIN’s profile in
the allergy/rhinitis marketplace, MedPointe increased the Wallace Pharmaceuticals’ field
sales force from 182 to 304 sales representatives. The Sepracor sales force, added to
MedPointe’s existing 304-person field sales force, will almost double the detailing effort
In commenting on this important initiative for MedPointe, Anthony H. Wild, Chairman
and CEO of MedPointe, said, “The purchase of full ownership rights to ASTELIN in the
US and Canada is of tremendous strategic and financial importance to MedPointe.
Combined with the expansion of our pharmaceutical field sales force earlier this year and
our recently announced co-promotion arrangement with Sepracor, we are in an excellent
position to drive the growth and profitability of this emerging, unique specialty
ASTELIN, a FDA-approved nasal spray, occupies a unique position within the
antihistamine marketplace. It is the only non-steroidal product indicated for use in
treating both seasonal allergic rhinitis and non-allergic, non-seasonal, vasomotor rhinitis.
The product, which is patent protected until 2010, has been approved for use in adults
and children five years of age and older.
Allergic rhinitis is an allergen-induced inflammation of the membranes lining the nose.
Allergic rhinitis includes seasonal allergic rhinitis, which is an allergic reaction that
occurs due to wind-borne pollen exposure. Common symptoms include sneezing, often
accompanied by a runny or clogged nose; coughing and postnasal drip; itchy eyes, nose
and throat; and red, burning or watery eyes.
Non-allergic vasomotor rhinitis is caused by exposure to common indoor and outdoor
triggers, including strong odors such as tobacco smoke, perfumes, colognes, hairspray,
soaps, detergents, cleaners, paint, and car exhaust fumes. Weather, especially changes in
humidity and temperature, can also trigger non-allergic vasomotor rhinitis. Spicy foods
and alcohol can trigger allergy-like symptoms such as runny nose, nasal congestion,
MedPointe was represented on the transaction by Bear, Stearns & Co. Inc.; Kirkland and
Ellis; and Simpson Thacher & Bartlett. Viatris was represented by Dr. Ferber & Partner
Viatris GmbH & Co. KG is a Frankfurt, Germany-headquartered multinational
pharmaceutical company which was recently spun out of Degussa AG. Viatris is
privately held and is currently controlled by the international private equity firm, Advent
International. Viatris has approximately 2,600 employees worldwide and operates in all
major European and North American markets, as well as Brazil. The company reported
annual turnover in 2001 of €480 Million.
MedPointe is a privately held company located in Somerset, New Jersey. Its prescription
pharmaceutical products division, Wallace Pharmaceuticals, specializes in respiratory,
cough/cold, pediatric and central nervous system products and maintains a manufacturing
facility in Decatur, Ill. Wampole Laboratories, MedPointe’s diagnostics division,
distributes a wide range of immunoassay-based diagnostic tests for use by hospitals,
physicians and reference laboratories. It was announced on August 8, 2002 that
MedPointe has entered into a definitive agreement to sell Wampole Laboratories to
Inverness Medical Innovations, Inc. For more information on MedPointe, Wallace
Pharmaceuticals or Wampole Laboratories, visit www.medpointeinc.com.
Astelin is a registered trademark of Wallace Laboratories.
Bruce E. Onofrey, OD, RPh, FAAO, FOGS ______________________________________________________________________________________ 8647 Rio Grande Blvd. NW Phone: (505) 262-7000 X 8328 day Albuquerque, NM 87114 (505) 262-3366 fax (505) 897-7057 home firstname.lastname@example.org EDUCATION: Residency: Veterans Administration Medical Center Albuquerque, New Mexico 1983 Illinois College of Opt
CINCINNATI HEALTH DEPARTMENT SCHOOL HEALTH PROGRAM SCALP RINGWORM INSTRUCTION SHEET (TINEA CAPITIS) *Your child must bring back a doctor’s note upon returning to school. If your child is diagnosed with scalp ringworm, the recommendations for treatment include the following: • Scalp ringworm is treated by an oral prescription medicine such as Griseofulvin, or Nizora